PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 29, 2026Journal of Medicinal Chemistry0 citationsOpen Access

Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration

View Full Paper
ERElena RoggiolaniMRMichela RosiniAMAnna Minarini

Key Points

  • To explore the therapeutic potential of allosteric kinase modulators in treating neurodegenerative diseases.
  • Discussed the roles of kinases in neurodegenerative processes
  • Highlighted developmental processes of CNS-directed allosteric kinase modulators
  • Reviewed validated allosteric modulators related to neuroprotection
  • Showcased neuroprotective properties and therapeutic potential of allosteric kinase modulators
  • Identified additional kinases for modulation that could benefit from allosteric approaches
  • Discussed future directions and challenges in the field

Abstract

Kinases represent one of the main targets of interest in recent years, completely revolutionizing small molecule anticancer therapy. Particularly, several medicinal chemistry strategies (e.g., covalent and allosteric inhibitors) allowed overcoming of the challenging selectivity issue, thus enabling the massive clinical translation of kinase inhibitors. However, the same success has not been detected yet for tackling neurodegenerative diseases, despite plenty of experimental evidence regarding kinases' pivotal roles in onset and development of neurodegenerative processes. In this perspective we highlight the therapeutic potential of allosteric kinase modulators in this respect, by showcasing the developmental processes and neuroprotective properties of CNS-directed allosteric kinases modulators developed so far. Moreover, we present additional kinases whose modulation is related to neuroprotection and featured by validated allosteric modulators not yet exploited in this context. This, along with a critical discussion on main drawbacks and future directions, may foster the development of allosteric kinase modulators in neurodegenerative diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Roggiolani et al. (2026) studied this question.

synapsesocial.com/papers/69f154e0879cb923c49453achttps://doi.org/10.1021/acs.jmedchem.5c03783
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy2010 · 126 citations
  2. 2PF-4708671, a specific inhibitor of p70 ribosomal S6 kinase 1, activates Nrf2 by promoting p62-dependent autophagic degradation of Keap12015 · 18 citations
  3. 3Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells2022 · 36 citations
  4. 4A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death2023 · 15 citations
  5. 5Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities2022 · 43 citations